$ cat ./records/gates-foundation-backs-path-biovac-partnership-as-first-african-c-2017.txt
Gates Foundation Backs PATH–Biovac Partnership as First African Company to Develop Group B Streptococcus Conjugate Vaccine
[RECORD.TXT] · cat --full
In May 2017, the Gates Foundation funded PATH to partner with South Africa's Biovac Institute to develop a polyvalent conjugate GBS vaccine, making Biovac only the third company globally — and the first in a developing country — to pursue an original GBS conjugate vaccine. More than half of all GBS newborn deaths occur in sub-Saharan Africa. The partnership established local LMIC manufacturing capability as central to ensuring any approved vaccine reaches the mothers and newborns who need it most.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Bill and Melinda Gates are made Commanders of France's Legion of Honour
Next →
Gates-Supported World Mosquito Program Achieves 95% Dengue Reduction in Medellín, Colombia
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.